Jens Mogensen
Angel Investor
Jens Mogensen is an Angel Investor.
- Total investments:
- 1
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries Jens Mogensen invests in
Stages Jens Mogensen invests in
Countries Jens Mogensen invests in
Investment Focus
Industry
- Medical 1 (100%)
- Life Science 1 (100%)
- Biotechnology 1 (100%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Thioredoxin Systems
|
Thioredoxin Systems develops innovative antibiotic regimen for complicated urinary tract infections. | $2.3M / Series A / Oct 30, 2024 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Jens Mogensen invest in?
Jens Mogensen invests primarily in Medical, Life Science and Biotechnology startups, most often at Series A stage. Most of the 1 investments tracked by Shizune back companies in Sweden. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Jens Mogensen last invest?
The most recent investment recorded for Jens Mogensen closed in Oct 2024. Shizune tracks 1 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
